US Urological Science

Urologic manifestations of systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease in which immune activity can injure the kidneys, blood vessels, nervous system and urinary tract. Its urologic manifestations range from protein and blood in the urine to hypertension, impaired kidney function, infection, obstruction and, rarely, neurogenic bladder. Some findings arise directly from lupus nephritis; others reflect antiphospholipid syndrome, treatment effects or an unrelated condition. That distinction matters because steroids and immunosuppressants may treat one cause while worsening infection or bleeding.

Recognition matters in Australia, where a person with SLE may first raise “blood in the urine”, swelling or urinary frequency with a GP rather than a specialist. Medicare generally requires a referral for subsidised specialist care, while the Pharmaceutical Benefits Scheme may subsidise some long-term medicines. GPs can arrange urine microscopy, kidney blood tests and imaging, then coordinate rheumatology, nephrology or urology. Access varies outside metropolitan centres, so telehealth and shared care are important.

Finding Key checks Main considerations
Proteinuria or foamy urine Urine albumin-to-creatinine ratio, kidney function, blood pressure Lupus nephritis, vascular disease or medication effects
Red, brown or pink urine Urine microscopy, culture, blood pressure Glomerular bleeding, infection, stones or a urinary tract lesion
Frequency, urgency or burning Urine culture, medication review, ultrasound Infection, lupus cystitis or treatment-related effects
Weak stream or retention Post-void residual, uroflowmetry, imaging Neurogenic bladder or ureteric obstruction
Swelling or reduced urine output Weight, blood pressure, kidney chemistry Active nephritis, fluid overload or renal vascular thrombosis

How lupus reaches the urinary tract

Most urinary abnormalities in SLE originate in the glomeruli. Immune complexes activate complement and inflammatory pathways, causing leakage of protein and red cells into urine. Class III or IV lupus nephritis, which is focal or diffuse proliferative disease, often produces an active sediment with dysmorphic red cells or red-cell casts. Class V membranous lupus nephritis may present mainly as heavy proteinuria with a quieter sediment.

Renal injury may also be vascular. In antiphospholipid syndrome, antibodies that promote clotting can cause renal microthrombi, hypertension and sudden reductions in kidney function rather than the classic inflammatory pattern. Rarely, lupus cystitis, ureteritis or inflammatory pelvic disease causes frequency, dysuria, haematuria or obstruction. These events warrant combined renal and urological assessment, not an assumption of simple UTI.

Infection and medication effects can resemble lupus nephritis, especially during immunosuppression. Urine culture, medication review and blood tests help separate them. In tropical locations such as Townsville and Darwin, clinicians may also consider locally acquired urinary infection more readily. For current issues, archives, abstracts and open-access urology papers, readers can browse the Urological Science journal.

Recognising renal and urinary disease

A structured assessment begins with symptoms, blood pressure, medicines, urine dipstick and microscopy. A spot urine albumin-to-creatinine ratio tracks protein loss, while estimated GFR and serial creatinine assess function. In established SLE, clinicians often check C3 and C4, anti-double-stranded DNA antibodies and antiphospholipid tests alongside routine chemistry. Falling complement and rising anti-dsDNA may support active nephritis but do not diagnose it alone.

Persistent haematuria should not simply be labelled as renal. Glomerular bleeding is typically microscopic, whereas clots, outlet symptoms or persistent visible blood can prompt urological imaging and cystoscopy. If the evaluation raises concern about prostate cancer—for example, an appropriate PSA pattern or abnormal digital rectal examination—specialists may use MRI fusion biopsy. Haematuria by itself does not prove malignancy or require prostate biopsy.

Lower urinary tract symptoms need their own pathway. Dysuria and frequency call for urine culture and assessment for infection, interstitial cystitis and medication effects. Weak stream, retention or a neurogenic bladder may require post-void residual measurement, ultrasound, uroflowmetry or urodynamics. A urologist can combine these tests with rheumatology and nephrology plans, particularly when lupus affects the spinal cord or causes ureteric obstruction.

Matching treatment to disease activity

Management is driven by kidney biopsy class, kidney function and extrarenal activity. Class III or IV disease commonly needs induction with glucocorticoids plus mycophenolate, or another specialist-selected regimen, followed by maintenance therapy. Class V disease may be managed with renin-angiotensin system blockade and supportive care unless proteinuria, hypertension or impaired function requires more intensive treatment. Rituximab, belimumab and other biologics may be considered in selected cases.

Supportive treatment is equally important: control blood pressure, reduce sodium and protein intake where appropriate, manage fluid and potassium, and avoid NSAIDs during active nephritis or with impaired kidney function. Hydroxychloroquine is usually continued because it reduces lupus activity and recurrence unless contraindicated. Vaccinations, pregnancy planning and review of interacting medicines should be coordinated before treatment changes.

Sexual dysfunction can accompany SLE because of fatigue, pain, mood, vascular disease, neuropathy or medication effects. An online tadalafil source may appear in search results, but convenience should not replace a lawful prescription and safety review. Australian prescribers and pharmacists should check the Therapeutic Goods Administration requirements and interactions with nitrates, riociguat and other cardiovascular medicines. Unregulated products may also contain inaccurate dosing or undeclared ingredients.

When urological procedures become necessary

Most urinary symptoms in SLE are managed without an operation. Acute retention or obstruction caused by thrombosis, ureteric stricture or inflammatory disease may require drainage with a ureteric stent or nephrostomy. Anticoagulation and infection risk should be planned with rheumatology and the operating team, and any obstruction needs timely renal follow-up.

If haematuria leads to cystoscopy and a bladder tumour is found, SLE itself is not a usual cause, so the tumour follows the standard pathway. Urologists commonly perform transurethral resection, and the published TURBT safety and efficacy evidence supports its central role in diagnosis and treatment. Immunosuppression may increase infection risk or affect healing, so pre-procedure planning matters.

Renal biopsy is often coordinated by nephrology rather than urology, and it remains essential for classifying active lupus nephritis. Before biopsy, teams check blood pressure, anaemia, platelet count and coagulation, then balance bleeding risk against the value of tissue diagnosis. Recurrent infection, bladder dysfunction and stones need separate urological plans so they are not mistaken for a flare of lupus.

A coordinated plan for Australian patients

Coordinated care is the safest approach in Australia, where SLE is usually managed across primary care and public specialist services. A GP can coordinate rheumatology, nephrology and urology, while severe disease may reach shared clinics in Melbourne, Sydney, Brisbane or Perth. Regional services around Townsville, Darwin and Alice Springs may rely on telehealth and visiting specialists. Aboriginal Medical Services and Aboriginal Community Controlled Health Organisations should be involved where appropriate, especially because kidney and rheumatic diseases affect many Aboriginal and Torres Strait Islander communities and access can be affected by remoteness.

Patients should also keep a written medication list, recent urine results and blood-pressure readings. New swelling, reduced urine output, visible clots, fever with flank pain or inability to urinate needs prompt medical review; fever with flank pain or retention may require urgent assessment. Daily life can be supported with vaccination planning, infection precautions, appropriate hydration and avoidance of unreviewed NSAIDs.

Before filling any prescription online, check the seller against the relevant Australian regulator and use a lawful pharmacy; consumer information on state pharmacy guidance should be read alongside current TGA and state pharmacy-authority advice. If urinary symptoms have appeared, contact your GP or treating team now, ask for a renal review and request urology assessment when haematuria persists or the bladder does not empty normally. Bring a medication list and recent urine results, and act promptly to prevent avoidable kidney injury, infection and prolonged urinary symptoms.